Capricor Therapeutics (CAPR) Return on Capital Employed (2011 - 2026)

Capricor Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 39.0% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 197.0% year-over-year to 39.0% in Q1 2026; TTM through Mar 2026 was 39.0%, a 197.0% increase from a year earlier, with the FY2025 full-year figure at 47.56%, down 208.0% from the prior year.
• Return on Capital Employed grew to 39.0% in Q1 2026 per CAPR's latest filing, from 52.66% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 38.45% in Q4 2024 and bottomed at 356.58% in Q3 2023.
• The 5-year median for Return on Capital Employed is 85.1% (2025), against an average of 109.16%.
• Across the five-year window, Return on Capital Employed sank 27119 bps in 2023 and surged 27650 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 104.48% in 2022, then plunged by 38 bps to 144.41% in 2023, then soared by 73 bps to 38.45% in 2024, then plunged by 37 bps to 52.66% in 2025, then advanced by 26 bps to 39.0% in 2026.
• Per Business Quant, the three latest CAPR Return on Capital Employed figures stand at 39.0% (Q1 2026), 52.66% (Q4 2025), and 85.1% (Q3 2025).